ARS Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
ARS Pharmaceuticals, Inc. (SPRY) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.70% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2026-03-31 was 3.70%, a 7.50% decline year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2025-03-31 was 4.00%.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.80%, a 5.56% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.60%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|
| 2026-06-30 | 3.70% 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | 3.70% 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | 3.80% 10-K · filed 2026-03-09 | ||
| 2025-06-30 | 3.90% 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | 4.00% 10-Q · filed 2026-05-15 | ||
| 2024-12-31 | 3.60% 10-K · filed 2026-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |